Pompe Disease in Infants: Improving the Prognosis by Newborn Screening and Early Treatment
Open Access
- 1 December 2009
- journal article
- Published by American Academy of Pediatrics (AAP) in PEDIATRICS
- Vol. 124 (6), e1116-e1125
- https://doi.org/10.1542/peds.2008-3667
Abstract
OBJECTIVE: Pompe disease causes progressive, debilitating, and often life-threatening musculoskeletal, respiratory, and cardiac symptoms. Favorable outcomes with early intravenous enzyme-replacement therapy and alglucosidase alfa have been reported, but early clinical diagnosis before the development of severe symptoms has rarely been possible in infants. METHODS: We recently conducted a newborn screening pilot program in Taiwan to improve the early detection of Pompe disease. Six of 206088 newborns screened tested positive and were treated for Pompe disease. Five had the rapidly progressive form of Pompe disease, characterized by cardiac and motor involvement, and were treated soon after diagnosis. The sixth patient was started on treatment at 14 months of age because of progressive muscle weakness. Outcomes were compared with treated patients whose disease was diagnosed clinically and with untreated historical control subjects. RESULTS: At the time of this report, patients had been treated for 14 to 32 months. The 5 infants who had early cardiac involvement demonstrated normalization of cardiac size and muscle pathology with normal physical growth and age-appropriate gains in motor development. The infant without cardiac involvement also achieved normal motor development with treatment. Survival in patients who had newborn screening was significantly improved compared with those in the untreated reference cohort (P = .001). Survival in the treated clinical comparators was reduced but not statistically different from that in the newborn screening group (P = .48). CONCLUSIONS: Results from this study indicate that early treatment can benefit infants with Pompe disease and highlight the advantages of early diagnosis, which can be achieved by newborn screening.This publication has 24 references indexed in Scilit:
- Multiplex Enzyme Assay Screening of Dried Blood Spots for Lysosomal Storage Disorders by Using Tandem Mass SpectrometryClinical Chemistry, 2008
- Adult‐onset glycogen storage disease type 2: clinico‐pathological phenotype revisitedNeuropathology and Applied Neurobiology, 2007
- Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe diseaseThe Journal of Pediatrics, 2006
- High-resolution Light Microscopy (HRLM) and Digital Analysis of Pompe Disease PathologyJournal of Histochemistry & Cytochemistry, 2005
- Direct Multiplex Assay of Lysosomal Enzymes in Dried Blood Spots for Newborn ScreeningClinical Chemistry, 2004
- Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human α-Glucosidase From MilkPEDIATRICS, 2004
- The Natural Course of Infantile Pompe’s Disease: 20 Original Cases Compared With 133 Cases From the LiteraturePEDIATRICS, 2003
- Infantile Pompe's disease, lipid storage, and partial carnitine deficiencyMuscle & Nerve, 1991
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958